1,721,089 research outputs found
A case of multiple intestinal atresias, brain anomalies, mental retardation, growth hormone deficiency and clitoris hypertrophy.
No full textNon-invasive aortic systolic pressure and pulse wave velocity estimation in a primary care setting: An in silico study
No full textProstanoids for chronic critical leg ischemia - A randomized, controlled, open-label trial with prostaglandin E-1
No full textAbstract: Background: No effective pharmacologic intervention is available for critical leg ischemia, a severe clinical condition associated with high morbidity and mortality.
Objective: To assess the safety and efficacy of prostaglandin E-1 in improving the prognosis and quality of life in patients with critical leg ischemia.
Design: Multicenter, centrally randomized, controlled, open-label trial.
Setting: 56 vascular surgery and angiology departments of the Italian National Health Service.
Patients: 1560 patients with chronic critical leg ischemia.
Interventions: In addition to routine treatments practiced in each center, patients were randomly assigned to receive either a daily intravenous infusion of 60 mu g of prostaglandin E-1 in the form of alprostadil-alpha-cyclodextrine (n = 771) or no prostaglandin E-1 (n = 789) during their hospital stay. The treatment period lasted for up to 28 days.
Measurements: A combined end point consisting of death and peripheral and cardiocerebrovascular illness (major amputation or persistence of critical leg ischemia, acute myocardial infarction, or stroke) evaluated at hospital discharge and during 6 months of follow-up.
Results: The incidence of the combined outcome measure was lower in the alprostadil group than in controls at hospital discharge (493 [63.9%] patients compared with 581 [73.6%] patients; relative risk, 0.87 [95% CI, 0.81 to 0.93]; P < 0.001) but differed only modestly at 6 months (348 of 661 [52.6%] patients compared with 387 of 673 [57.5%] patients; relative risk, 0.92 [CI, 0.83 to 1.01]; P = 0.074). Most of the observed benefit was due to recovery from critical leg ischemia.
Conclusions: Short-term treatment with alprostadil-alpha-cyclodextrine provides patients with critical leg ischemia clinical benefit that is apparent in the short term but decreases over time
Going Beyond Counting First Authors in Author Co-citation Analysis
Full text linkThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
ARE GILBERT’S SYNDROME AND LIVER INVOLVEMENT GENETICALLY LINKED IN INFECTIOUS MONONUCLEOSIS?
No full text- …
